Moebus 2007.

Methods	randomized controlled trial, not placebo‐controlled
Participants	n = 643, breast cancer (high risk, stage II/IIIA; M0); concomitant treatment: chemotherapy
Interventions	drug = Epoetin alpha dose = 150 IU/kg sc TIW hb‐target = 13‐14 g/dL planned ESA duration = during chemotherapy
Outcomes	Primary: transfusion, Hb; secondary: recurrence free survival, overall survival, relapse, QoL
Notes	study number = 22515
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Low risk	computer generated
Allocation concealment?	Low risk	central randomization